PineTree Therapeutics (2)

PineTree Therapeutics (2)

  • Founded: 2019
  • Location: Cambridge, MA
  • Employee range: 11 - 50
  • Clinical stage: RD
  • Therapy area: Oncology
  • Drug types: ONC, INF
  • Lead product: TAER-TAB platform
  • Product link:
  • Funding: $23.5M A1 Jun 2022
  • Investors: InterVest, SK Securities, DSC Investment, J Curve Investment, Samho Green Investment, SJ Investment Partners

job board

Short description:

Antibody Therapy, Virus-Targeting Recombinant Agent

Drug notes:

ViTRAP platform RD infectious diseases

Long description:

PineTree Therapeutics is developing novel medicines to combat drug resistance in oncology. To overcome the shortcomings of existing therapies, PineTree is creating targeted protein degraders. This includes PineTree’s AbReptorTM, a transformative modular bi-specific and multi-specific antibody platform designed to degrade membrane-bound and extracellular proteins. AbReptor works by co-engaging a target protein, either surface-receptor or extracellular proteins with another proprietary receptor target. PineTree’s lead candidate, PTX-299, a bispecific antibody for EGFR-driven cancers is not in IND-enabling studies.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy